Loxo Oncology Seeks FDA Approval For Breakthrough Drug

Jun 5, 2017, 11:40 by Michael Croft

Forbes | Loxo's therapy Larotrectinib demonstrates 76% confirmed objective response rate in TRK fusion adult and pediatric cancers as presented at the American Society of Clinical Oncology annual meeting.

June 05, 2017 | Loxo's therapy Larotrectinib demonstrates 76% confirmed objective response rate in TRK fusion adult and pediatric cancers as presented at the American Society of Clinical Oncology annual meeting. Forbes